^
    Back
    Association details:
    Biomarker:BRAF V600E + BRAF V600K
    Cancer:Melanoma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

    Published date:
    07/28/2023
    Excerpt:
    Eligible patients were 18 years and older with a histologically confirmed diagnosis of locally advanced, unresectable/metastatic cutaneous melanoma or unknown primary melanoma (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV) and the presence of BRAFV600E and/or BRAFV600K mutation in tumor tissue....The median PFS (95% CI) was 12.9 months (10.9 to 14.9) for COMBO300 versus 9.2  months (7.4 to 11.1) for ENCO300 (parts 1  and  2) and 7.4  months (5.6 to 9.2) for ENCO300 (part 2)....COMBO300 improved PFS, ORR, and tolerability compared with ENCO300, confirming the contribution of binimetinib to efficacy and safety.
    DOI:
    10.1200/JCO.22.02322
    Trial ID:
    COLUMBUS
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

    Excerpt:
    ...- Confirmed BRAF V600E/V600K activating mutation reported in the data based on laboratory or genetic analysis results....
    Trial ID:
    NCT05954546